Succeeding Where Big Pharma Has Failed
We understand why Big Pharma has been unable to develop a disease-modifying OA therapy, and our A2M-based therapeutic platform addresses their deficiencies.
Nature’s Blueprint, Perfected
Our first-generation OA therapy leverages the therapeutic power of the natural A2M protein. Now, we are “perfecting” Nature’s Design with CYT-108, our novel “super A2M” biopharmaceutical in FDA clinical trials.
For the People, By the People
Biopharma is almost exclusively capitalized and owned by Venture Capitalists, Wall Street funds, and Big Pharma. Cytonics is flipping this script and placing the power in the hands of those that need us to succeed the most: The People.
PARTNERED WITH RESEARCHERS FROM
More than 500 million people live with osteoarthritis. Today’s treatments only manage the symptoms.
Painkillers, steroid injections and joint lubricants can ease pain for a while, but none is approved to slow the disease itself. Many people eventually need a joint replacement.
Pioneering Innovation In Drug Discovery
10,000+
Patients treated with APIC™
Phase 1
Complete for CYT-108
25+
International patents
7,800+
Shareholders in 63 countries
Our Ambassadors
Frequently Asked Questions
Do you want to learn more about us, let’s go the blog page.
Investor Presentation
Cytonics: a biotech rebellion
Get updates on CYT-108 and the science behind it.
The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.
This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
© 2026 Cytonics Corporation. All rights reserved.